Anivive Lifesciences Strengthens Leadership with Dr. Stephen Fisher
Anivive Lifesciences, a leading software-driven pet pharmaceutical company, has appointed Dr. Stephen Fisher, DVM, to its Board of Directors. This significant step forward reflects Anivive's evolution from a research-intensive organization to one poised for commercial success, showcasing its dedication to addressing the critical needs in pet healthcare.
Dr. Fisher's Expertise and Experience
Dr. Fisher brings over 50 years of invaluable experience in veterinary medicine and business strategy. As the former Global Vice President of Commercial at MARS Veterinary Health, he effectively managed procurement for a staggering 30 million pets annually across more than 3,000 veterinary hospitals. His extensive expertise in the animal health sector will greatly benefit Anivive as the company pushes to introduce innovative therapies to the market.
Impact on Anivive's Transition
"Steve's appointment couldn't come at a more critical time," said Dylan Balsz, Founder and CEO of Anivive. The company is advancing its first-ever Valley fever vaccine through the regulatory landscape while expanding its oncology diagnostics. Dr. Fisher's wealth of knowledge in pricing strategy, product placement, and distribution strategies will be essential as Anivive seeks to deliver groundbreaking solutions to veterinarians and pet owners around the globe.
Path to Leadership
Dr. Fisher's distinguished career began as a small animal veterinarian in Illinois, where he adeptly transformed a solo practice into a successful 10-practice veterinary group that later became part of Veterinary Centers of America (VCA). He played a crucial role during VCA's growth, aiding in its IPO and subsequent acquisition by MARS, Incorporated in 2017. After this acquisition, Dr. Fisher headed MARS Veterinary Health's global procurement operations until his retirement earlier this year.
Commitment to Veterinary Advancement
With a career marked by significant achievements, Dr. Fisher has established himself as a respected figure in veterinary medicine. In addition to his corporate roles, he has contributed to various nonprofit organizations and scientific boards, including the Arizona Humane Society and the Morris Animal Foundation. His advocacy for a Valley fever vaccine emphasizes his dedication to improving animal health.
Valley Fever Vaccine Development
The Valley fever vaccine Anivive is developing is especially crucial, as this infection affects nearly 30 million dogs and 100 million people within southern regions of the United States. While the prevalence of this disease has escalated dramatically over the last decade, no preventive vaccine has been available, making Anivive's efforts increasingly significant. The company has received a $33 million contract from the National Institute of Allergy and Infectious Diseases to propel the vaccine's development, marking a significant milestone in veterinary health.
To stay ahead in the market, Anivive has also launched Engage, a direct-to-veterinarian platform that facilitates efficient ordering of specialty diagnostics and genomic sequencing. This innovative approach has successfully managed over 25,000 orders since its inception, reflecting the company's commitment to leveraging technology for better animal care.
About Anivive Lifesciences
Anivive Lifesciences stands at the forefront of the intersection between biotechnology and veterinary medicine. Our mission focuses on reshaping animal healthcare through cutting-edge advancements in AI, developing novel treatments aimed at life-threatening conditions in pets. By introducing first-in-class therapeutics in areas such as oncology, antivirals, and antifungal vaccines, we are redefining the landscape of veterinary care. To learn more about our initiatives, visit anivive.com.
Frequently Asked Questions
Who is Dr. Stephen Fisher?
Dr. Stephen Fisher is a veterinary expert with over 50 years of experience, most recently serving as the Global Vice President at MARS Veterinary Health.
What is Anivive Lifesciences?
Anivive Lifesciences is a pet pharmaceutical company focused on developing innovative treatments for pets, employing biotech and AI technologies.
What role will Dr. Fisher play at Anivive?
Dr. Fisher will serve on Anivive's Board of Directors, helping to guide the company's commercial strategies and product development.
What is the Valley fever vaccine?
The Valley fever vaccine is Anivive's groundbreaking vaccine aimed at preventing a significant fungal infection impacting pets and people in specific regions.
What services does Anivive's Engage platform provide?
Engage is Anivive's direct-to-veterinarian platform that offers specialty diagnostics and genomic sequencing for veterinarians to enhance pet care.
